Join us as we analyze Quest Diagnostics and uncover whether this lab giant is a smart investment choice for the future. With insights from industry experts, you won't want to miss this evaluation!
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with Quest (NYSE:DGX).
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.64 per share was 2.5% above analysts’ consensus estimates.
Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX)
jumped 6.4% in the morning session after the company reported strong second-quarter financial results that beat Wall Street expectations and raised its full-year guidance.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) announced better-than-expected revenue in Q2 CY2025, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.62 per share was 1.9% above analysts’ consensus estimates.
